CoChat

Long‐term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors

Open access
Hackett, Geoffrey, Cole, Nigel, Mulay, Akhilesh, Strange, Richard C., Ramachandran, Sudarshan · 2019 · BJU International
Cited by 43

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Objectives: To further characterize the beneficial impact of testosterone replacement therapy ( TRT ) on the association between mortality and hypogonadism ( HG ) in men with type 2 diabetes (T2 DM ), by determining, firstly, if changes in cardiovascular disease ( CVD ) risk factors after TRT play a role, secondly, whether the reduction in mortality is lost when TRT is discontinued and, finally, the presence of subgroups where benefit may be greater. Materials and Methods: We studied 857 men with T2 DM , screened for the BLAST randomized controlled trial, over 3.8 years of follow‐up. The men were stratified first by testosterone levels: group 1: total testosterone ( TT ) >12 nmol/L and free testosterone ( FT ) >0.25 nmol/L; Group 2: TT ≤12 nmol/L or FT ≤0.25 nmol/L. Group 2 was further stratified into those not on TRT (Group 2a) and those on TRT (Group 2b). Group 2b was further stratified by whether TRT was discontinued (Group 2b1) or not (Group 2b2). The principal outcome, mortality, was studied using Cox regression. Results: We found that TRT was not associated with improvements in CVD risk factors. CVD risk factors (baseline and changes during follow‐up) were not associated with mortality. Men in Group 1 and Group 2b were found to have lower mortality (reference: Group 2a), even with CVD risk factors included in the regression models. Mortality was lower in men in Group 2b1 (6.2%) and Group 2b2 (0%) compared with those in Group 2a (16.9%). The lower mortality associated with Group 1 and Group 2b was observed primarily in older (>64.6 years) and less overweight (≤93.8 kg) men. Conclusions: The benefits associated with normal testosterone levels and TRT (even after discontinuation) do not appear to be related to improvements in the CVD risk factors studied. In view of TRT having greater impact in men of lower weight, better outcomes may be achieved with concurrent TRT and weight reduction programmes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bju.14536

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 43

Metadata

Authors
Hackett, G., Cole, N., Mulay, A., Strange, R. C., & Ramachandran, S.
Venue
BJU International
Publisher
Wiley
Published
2018-10-16
Volume
123
Issue
3
Pages
519-529
ISSN
  • 1464-4096 (ISSN-L)
  • 1464-410X
OpenAlex
W2891885274
Cited by
43
References
14
FWCI
3.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long‐term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors. https://app.cochat.ai/papers/10.1111/bju.14536
The paper
Hackett, G., Cole, N., Mulay, A., Strange, R. C., & Ramachandran, S. (2019). Long‐term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors. BJU International. https://doi.org/10.1111/bju.14536

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.